2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
Hu Y, Narayan A, Xu Y, Wolfe J, Vu D, Trinh T, Kantak C, Ivy S, Eder J, Deng Y, LoRusso P, Kim J, Patel A. Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors. JCO Precision Oncology 2024, 8: e2300289. PMID: 38412387, PMCID: PMC10914240, DOI: 10.1200/po.23.00289.Peer-Reviewed Original ResearchConceptsCell-free circulating tumor DNANon-small-cell lung cancerSmall-cell lung cancerTriple-negative breast cancerPancreatic ductal adenocarcinomaAdvanced solid tumorsVariant allele fractionRadiographic responseOverall survivalCombination therapySolid tumorsCtDNA levelsLung cancerPretreated advanced solid tumorsDays of combination therapyMetastatic pancreatic ductal adenocarcinomaResponse to anticancer therapyAssociated with disease progressionProgression-free survivalPlasma samplesLead-inPoly(ADP-riboseInferior OSTumor DNASurvival outcomes
2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Kim J, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer P, Shyr Y, Ivy SP, LoRusso P. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. The Oncologist 2021, 26: e1104-e1109. PMID: 33742489, PMCID: PMC8265343, DOI: 10.1002/onco.13758.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaFemaleHumansMutationOvarian NeoplasmsPancreatic NeoplasmsPhthalazinesPiperazinesQuinazolinesVascular Endothelial Growth Factor AConceptsMetastatic pancreatic adenocarcinomaHomologous recombination DNA repair deficiencyMetastatic pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaOlaparib combinationStable diseaseBRCA mutationsAdverse eventsDuctal adenocarcinomaCommon treatment-related adverse eventsVascular endothelial growth factor receptor inhibitorEndothelial growth factor receptor inhibitorTreatment-related adverse eventsGrowth factor receptor inhibitorsPrior systemic chemotherapyMedian overall survivalObjective response rateGermline BRCA mutationsBest overall responseExpression of BRCA1/2Restaging scanCancer cell linesPrimary endpointStudy drugSystemic chemotherapy
1998
Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma
Zalupski M, Shields A, Philip P, Kraut M, LoRusso P, Heilbrun L, Vaitkevicius V. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Investigational New Drugs 1998, 16: 93-96. PMID: 9740550, DOI: 10.1023/a:1006087114621.Peer-Reviewed Original ResearchConceptsPancreatic carcinomaBroad preclinical antitumor activityUntreated advanced pancreatic cancerAdvanced pancreatic cancerAdvanced pancreatic carcinomaPhase II trialSchedule of administrationPreclinical antitumor activityModerate neutropeniaPredictable toxicityII trialMajor toxicityClinical efficacyMild neurotoxicityPancreatic cancerClinical developmentPatientsPyrazoloacridinePhase IAntitumor activitySolid tumor selectivityTumor selectivityCarcinomaDoseToxicity
1990
Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.
LoRusso P, Wozniak A, Polin L, Capps D, Leopold W, Werbel L, Biernat L, Dan M, Corbett T. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Research 1990, 50: 4900-5. PMID: 2165850.Peer-Reviewed Original ResearchMeSH KeywordsAcridinesAdenocarcinomaAnimalsAntineoplastic AgentsCarcinoma, Intraductal, NoninfiltratingCell SurvivalColonic NeoplasmsDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorMiceMice, Inbred BALB CMice, Inbred C3HMice, Inbred C57BLMice, Inbred DBAMice, Inbred StrainsPancreatic NeoplasmsPyrazolesTumor Cells, CulturedConceptsInfusional therapyCentral nervous system toxicityNervous system toxicityDisk diffusionPreclinical toxicology evaluationColon adenocarcinoma 38Log cell killMain toxicityBolus therapySystem toxicityCellular cytotoxicityMurine L1210 leukemiaSolid tumorsInfusion studiesTotal doseCell killAntitumor efficacyHuman investigationsL1210 leukemiaAgar disk diffusionTherapySolid tumor selectivityTumor selectivityToxicology evaluationToxicityActivity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice
Mucci-LoRusso P, Polin L, Biernat L, Valeriote F, Corbett T. Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice. Investigational New Drugs 1990, 8: 253-261. PMID: 2177044, DOI: 10.1007/bf00171834.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsCarcinoma, Intraductal, NoninfiltratingColonic NeoplasmsDrug Screening Assays, AntitumorEllipticinesFemaleHumansInjections, IntravenousLeukemia L1210MaleMammary Neoplasms, ExperimentalMiceMice, Inbred StrainsNeoplasm TransplantationNeoplasms, ExperimentalPancreatic Neoplasms
1989
Activity of batracylin (NSC-320846) against solid tumors of mice
Mucci-LoRusso P, Polin L, Bissery M, Valeriote F, Plowman J, Luk G, Corbettv T. Activity of batracylin (NSC-320846) against solid tumors of mice. Investigational New Drugs 1989, 7: 295-306. PMID: 2557298, DOI: 10.1007/bf00173759.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsAntineoplastic AgentsCarcinoma, Intraductal, NoninfiltratingCell SurvivalCells, CulturedColonic NeoplasmsDrug Administration ScheduleDrug Screening Assays, AntitumorHumansMammary Neoplasms, ExperimentalMiceMice, Inbred StrainsNeoplasms, ExperimentalPancreatic NeoplasmsQuinazolinesTumor Cells, Cultured